Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.
Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RS, Hosford DA, Dvergsten C, Segreti AC, Beaver JS, Toler SM, Jett JE, Dunbar GC.
Walling D, et al. Among authors: hosford da.
Schizophr Bull. 2016 Mar;42(2):335-43. doi: 10.1093/schbul/sbv072. Epub 2015 Jun 12.
Schizophr Bull. 2016.
PMID: 26071208
Free PMC article.
Clinical Trial.